Table 4.
Performance of Models for the composite endpoint of all-cause mortality and readmission due to heart failure
| Marker | C-statistic (p value) | Nagelkerke’s R2 | cNRI | Reclassification |
|---|---|---|---|---|
| Composite endpoint | ||||
| Clinical model (CM) | 0.815 | 0.645 | ||
| CM + Stanniocalcin-2 | 0.821 (p = 0.100) | 0.660 | 0.125 (− 0.053–0.363) | 3.8% (0.9–6.9%) |
| CM + IGFBP-4 | 0.823 (p = 0.113) | 0.671 | 0.270 (0.064–0.431) | 5.0% (2.2–8.9%) |
| CM + Stanniocalcin-2 + IGFBP-4 | 0.826 (p = 0.036) | 0.677 | 0.176 (0.001–0.420) | 6.2% (3.1–9.6%) |
| All-cause mortality | ||||
| Clinical model (CM) | 0.807 | 0.636 | ||
| CM + Stanniocalcin-2 | 0.808 (p = 0.555) | 0.646 | 0.129 (− 0.129–0.330) | 2.4% (0.3–4.8%) |
| CM + IGFBP-4 | 0.814 (p = 0.241) | 0.662 | 0.248 (0.001–0.412) | 3.7% (1.2–6.6%) |
| CM + Stanniocalcin-2 + IGFBP-4 | 0.814 (p = 0.204) | 0.664 | 0.185 (− 0.041–0.433) | 4.1% (1.6–7.0%) |
| Readmission due to heart failure | ||||
| Clinical model (CM) | 0.861 | 0.802 | ||
| CM + Stanniocalcin-2 | 0.872 (p = 0.211) | 0.825 | 0.256 (− 0.129–0.653) | 1.31% (0.2–3.0%) |
| CM + IGFBP-4 | 0.861 (p = 0.103) | 0.806 | 0.114 (− 0.285–0.446) | 0.4% (0.0–1.9%) |
| CM + Stanniocalcin-2 + IGFBP-4 | 0.869 (p = 0.413) | 0.823 | 0.239 (− 0.148–0.611) | 1.6% (0.3–3.1%) |
Clinical model includes: age, sex, history of arterial hypertension, diabetes mellitus, heart failure, myocardial infarction, glomerular filtration rate and left ventricular ejection fraction
IGFBP-4 insulin-like growth factor binding protein-4